Get access

Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs

Authors

  • Guoliang Lv,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Lifu Zhao,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Anye Zhang,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Weibo Du,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Yu Chen,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Chengbo Yu,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Xiaoping Pan,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Yimin Zhang,

    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    Search for more papers by this author
  • Tao Song,

    1. Institute of Electrical Engineering, Chinese Academy of Sciences, Beijing, China
    Search for more papers by this author
  • Jiansheng Xu,

    1. Institute of Electrical Engineering, Chinese Academy of Sciences, Beijing, China
    Search for more papers by this author
  • Yu Chen,

    1. Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China
    Search for more papers by this author
  • Lanjuan Li

    Corresponding author
    1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759
    • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; telephone: 86-571-87236759; fax: 86-571-87236759.
    Search for more papers by this author

  • Guoliang Lv and Lifu Zhao contributed equally to this study.

Abstract

Bioartificial liver (BAL) support system has been proposed as potential treatment method for end-stage liver diseases. We described an improved BAL system based on a choanoid fluidized bed bioreactor containing alginate–chitosan encapsulated primary porcine hepatocytes. The feasibility, safety, and efficiency of this device were estimated using an allogeneic fulminant hepatic failure (FHF) model. FHF was induced with intravenous administration of D-galactosamine. Thirty FHF pigs were divided into three groups: (1) an FHF group which was only given intensive care; (2) a sham BAL group which was treated with the BAL system with empty encapsulation, and (3) a BAL group which was treated with the BAL system containing encapsulated freshly isolated primary porcine hepatocytes. The survival times and biochemical parameters of these animals were measured, and properties of the encapsulations and hepatocytes before and after perfusion were also evaluated. Compared to the two control groups, the BAL-treated group had prolonged the survival time and decreased the blood lactate levels, blood glucose, and amino acids remained stable. No obvious ruptured beads or statistical decline in viability or function of encapsulated hepatocytes were observed. This new fluidized bed BAL system is safe and efficient. It may represent a feasible alternative in the treatment of liver failure. Biotechnol. Bioeng. 2011;108:2229–2236. © 2011 Wiley Periodicals, Inc.

Ancillary